Biotech stocks in trouble? Immatics shares plunge after $150m funding news shocks investors
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has seen its shares decline significantly after announcing a $150 million public offering. The announcement came as a surprise to investors, with the stock experiencing a sharp drop of approximately 10%, closing at $9.95 from its previous levels above $11. This downturn has […]